Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: A randomized placebo-controlled trial

Inflammatory Bowel Diseases

Volumn 15, Issue 7, 2009, Pages 1055-1061

  Levine, Arie ^a,j   Kori, Michal ^b,j   Dinari, Gabriel ^c,j   Broide, Efrat ^j   Shaoul, Ron ^e,j   Yerushalmi, Baruch ^f,j   On, Avi ^g,j   Bujanover, Yoram ^h,j   Pröls, Markus ⁱ   Greinwald, Roland ⁱ   Granot, Esther ^j   Weizman, Zvi ^j   Lerner, Aaron ^j   Pacht, Avi ^j   Yaron, Ayala ^j   Reif, Shimon ^j   Wald, David ^j   Silbermintz, Arie ^j  

^a TEL AVIV UNIVERSITY   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

^c Schneider Childrens Hospital   (Israel)

^d ASSAF HAROFEH MEDICAL CENTER   (Israel)

^e BNAI ZION MEDICAL CENTER   (Israel)

^f BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^g Poriah Medical Center   (Israel)

^h Safra Childrens Hospital   (Israel)

ⁱ Dr Falk Pharma   (Germany)

^j NONE

more..

Author keywords

Budesonide; Child; Colitis; Crohn's disease; Inflammatory bowel disease; Pediatric

Indexed keywords

ALBUMIN; BUDENOFALK; BUDESONIDE; C REACTIVE PROTEIN; HEMOGLOBIN; PLACEBO; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER;

ACNE; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; COLON DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HAIR; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; ILEUM DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCHOOL CHILD; SIDE EFFECT; TREATMENT DURATION; COMPARATIVE STUDY; FOLLOW UP; IMMUNOLOGY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; BUDESONIDE; CHILD; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PLACEBOS; REMISSION INDUCTION; YOUNG ADULT;

EID: 69449099032     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20881     Document Type: Article

References (24)

1. Kim SC, Ferry GD. Inflammatory bowel disease in pediatric and adolescent patient: clinical, therapeutic and psychological considerations. Gastroenterology. 2004;126:1550-1560.
2. Griffiths AM, Nguyen P, Smith C, et al. Growth and clinical course of children with Crohn's disease. Gut. 1993;34:939-943.
3. Levine A, Kugathasan S, Annese V, et al. Pediatric onset Crohn's colitis is characterized by genotype dependent age-related susceptibility. Inflamm Bowel Dis. 2007;13:1509-1515.
4. Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr. 2005;146:35-40.
5. Caprilli R, Gassul M, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut. 2006;55(Suppl 1):i36-58.
6. Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4:1124-1129.
7. Levine A, Milo T, Büller H, et al. Consensus and controversy in the management of pediatric Crohn's disease: an international survey. J Pediatr Gastroenterol Nutr. 2003;36:464-469.
8. Escher JC, Taminiau JA, Nieuwenhuis E, et al. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis. 2003;9:34-58.
9. Thomson OO, Cortot A, Jewell DA, et al. Comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med. 1998;339:370-374.
10. Bar Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenteroloy. 1998;115:835-840.
11. Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut. 1997;41:209-214.
12. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. N Engl J Med. 1994;331:836-841.
13. Levine A, Weizman Z, Shamir R, et al. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn's disease. J Pediatr Gastroenterol Nutr. 2003;36:248-252.
14. Levine A, Broide E, Stein M, et al. Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children. J Pediatr. 2002;140:75-80.
15. Escher JC, European Collaborative Research Group on Budesonide in Pediatric IBD. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol. 2004;16:47-54.
16. Möllmann HW, Hochhaus G, Tromm A, et al. Pharmacokinetics of budesonide after oral delivery of pH-modified release capsules (Budenofalk) in healthy volunteers and patients with Crohn's disease and ileostomy patients. J Gastroenterol Hepatol. 1995;10(Suppl 4):A305.
17. Tromm A, Mölmann HW, Barth J, et al. Results of a pharmacodynamic study in healthy volunteers after oral treatment with budesonide. Falk Symp. 1993;73:6-8, A103.
18. Caesar I, Gross V, Andus T, et al. Dreiarmige Dosisfindungsstudie mit dem topischen Steroid Budesonid bei Patienten mit aktiver und postaktiver Ileocolitis Crohn. Z Gastroenterol. 1996;34:578.
19. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis - the Porto criteria. J Pediatr Gastroenterol Nutr. 2005;41:1-7.
20. Hyams JS, Ferry G, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
21. Otley A, Loonen H, Parekh N, et al. Assessing activity of pediatric Crohn's disease: which index to use? Gastroenterology. 1999;116:527-531.
22. Kolkman JJ, Möllmann HW, Möllmann AC, et al. Evaluation of oral budesonide in the treatment of active distal ulcerative colitis. Drugs Today. 2004;40:589-601.
23. Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 1994;331: 842-825.
24. Griffiths AM, Otley A, Hyams J, et al. A review of activity indices and end points for clinical trials in children with Crohn's disease. Inflamm Bowel Dis. 2005;11:185-196.